Betanal care

Hauptinformation

  • Handelsname:
  • Betanal care
  • Darreichungsform:
  • EC Emulsionskonzentrat
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Betanal care
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Herbizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • W-6827
  • Letzte Änderung:
  • 14-11-2018

Packungsbeilage

Handelsbezeichnung: Betanal care

Pflanzenschutzmittelverzeichnis (Stand: 06.11.2018)

Produktkategorie:

Bewilligungsinhaber:

Eidg. Zulassungsnummer:

Herbizid

Bayer (Schweiz) AG

W-6827

Stoff(e):

Gehalt:

Formulierungscode:

Wirkstoff: Phenmedipham

Wirkstoff: Desmedipham

15.5 % 160 g/l

15.5 % 160 g/l

EC Emulsionskonzentrat

Anwendungen

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

G Rande

Einj

hrige Dicotyledonen (Unkr

uter)

Aufwandmenge: 1.5 l/ha

Anwendung: Nachauflauf.

1, 2

Futterr

Zuckerr

Einj

hrige Dicotyledonen (Unkr

uter)

Aufwandmenge: 1.5 l/ha

Anwendung: Nachauflauf.

1, 3

Auflagen und Bemerkungen:

Splitbehandlung (angegebene Aufwandmenge entspricht total bewilligter Menge).

2-3 Splitbehandlungen, 0.5-0.75 l/ha je Split.

2-4 Splitbehandlungen, 0.375-0.75 l/ha je Split.

Gefahrenkennzeichnungen:

Darf nicht in die H

nde von Kindern gelangen.

EUH 401 Zur Vermeidung von Risiken f

r Mensch und Umwelt die Gebrauchsanleitung

einhalten.

H410 Sehr giftig f

r Wasserorganismen mit langfristiger Wirkung.

SP 1 Mittel und/oder dessen Beh

lter nicht in Gew

sser gelangen lassen.

Signalwort:

Achtung

Gefahrensymbole und -bezeichnungen:

Kurzkennzeichnung

GHS09

Symbol

Gefahrenbezeichnung

ssergef

hrdend

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erw

hnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

14-11-2018

FDA alerts doctors, patients about risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices

FDA alerts doctors, patients about risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices

FDA alerted health care providers and patients about the serious complications that can occur when using medications not approved for use with implanted pumps that deliver medication into the spinal fluid to treat or manage pain.

FDA - U.S. Food and Drug Administration

7-11-2018

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Vita Health Products is voluntarily recalling several store-brand (Care, Exact, Life, and Pharmasave) over-the-counter drugs used for pain or sinus relief because of a labelling issue. Consumers may be unable to peel open the wrap-around label on the bottle to access the warning statements, or the label may not peel off completely, which may make it difficult to read some of the important safety information.

Health Canada

5-10-2018

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of a new device, the Bose Hearing Aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment (hearing loss). This is the first hearing aid authorized for marketing by the FDA that enables the user to fit, program and control the hearing aid on his or her own, without assistance from a health care provider.

FDA - U.S. Food and Drug Administration

25-9-2018

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

FDA - U.S. Food and Drug Administration

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

17-9-2018

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

28-8-2018

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

Pfizer Consumer Healthcare, a division of Pfizer Inc., is voluntarily recalling one lot of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle because of customer complaints that the dosage cup provided is marked in teaspoons and the instructions on the label are described in milliliters (mL).

FDA - U.S. Food and Drug Administration

28-8-2018

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market.

FDA - U.S. Food and Drug Administration

22-8-2018

Dringende Sicherheitsinformation zu Rotating IV pole von GE Healthcare Clinical Systems (Ohmeda Medical)

Dringende Sicherheitsinformation zu Rotating IV pole von GE Healthcare Clinical Systems (Ohmeda Medical)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-8-2018

Dringende Sicherheitsinformation zu Hematek Modified Wright / Wright-Giemsa Stain Pack von Siemens Healthcare Diagnostics Inc. Tarrytown

Dringende Sicherheitsinformation zu Hematek Modified Wright / Wright-Giemsa Stain Pack von Siemens Healthcare Diagnostics Inc. Tarrytown

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-8-2018

Dringende Sicherheitsinformation zu RAPIDPoint 405 500 and RAPIDLab 1245 1265 von Siemens Healthcare Diagnostics Inc. Tarrytown

Dringende Sicherheitsinformation zu RAPIDPoint 405 500 and RAPIDLab 1245 1265 von Siemens Healthcare Diagnostics Inc. Tarrytown

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-8-2018

Dringende Sicherheitsinformation zu Direct Radiography system DX-D 600 von Agfa HealthCare N.V.

Dringende Sicherheitsinformation zu Direct Radiography system DX-D 600 von Agfa HealthCare N.V.

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

17-8-2018

Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers - Risk of Mortality and Stroke

Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers - Risk of Mortality and Stroke

FDA has reviewed the final results from the post-approval study conducted by SynCardia Systems, LLC. for their Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System (C2 Driver System). These final results indicate a higher mortality rate and higher stroke rate for patients initially supported with the C2 Driver System compared to patients initially supported with the previous generation driver, the Circulatory Support System (CSS) Console.

FDA - U.S. Food and Drug Administration

16-8-2018

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

FDA - U.S. Food and Drug Administration

11-8-2018

Dringende Sicherheitsinformation zu AEROtube-ET01-65M-SET, Endotrachealtubus-SET,mit Manschette, einzeln steril verpackt, 6,5 mm,CH 26 von HUM Gesellschaft für Homecare und Medizintechnik mbH

Dringende Sicherheitsinformation zu AEROtube-ET01-65M-SET, Endotrachealtubus-SET,mit Manschette, einzeln steril verpackt, 6,5 mm,CH 26 von HUM Gesellschaft für Homecare und Medizintechnik mbH

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

Dringende Sicherheitsinformation zu AXIOM MULTIX, MT, ACSS,P,N, AXIOM MULTIX, MT, ACSS,N, AXIOM MULTIX, MT, AXIOM Vertix Solitaire M-System_T, AXIOM ARISTOS VX Plus von Siemens Healthcare GmbH, X-Ray Products (XP)

Dringende Sicherheitsinformation zu AXIOM MULTIX, MT, ACSS,P,N, AXIOM MULTIX, MT, ACSS,N, AXIOM MULTIX, MT, AXIOM Vertix Solitaire M-System_T, AXIOM ARISTOS VX Plus von Siemens Healthcare GmbH, X-Ray Products (XP)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

Dringende Sicherheitsinformation zu Ysio, Ysio Max, Ysio Fully, Ysio Semi von Siemens Healthcare GmbH, X-Ray Products (XP)

Dringende Sicherheitsinformation zu Ysio, Ysio Max, Ysio Fully, Ysio Semi von Siemens Healthcare GmbH, X-Ray Products (XP)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

8-8-2018

Risks Associated with Use of Rupture of Membranes Tests - Letter to Health Care Providers

Risks Associated with Use of Rupture of Membranes Tests - Letter to Health Care Providers

The FDA is reminding health care providers that tests to detect rupture of the amniotic membranes should not be used without other clinical assessments to make critical patient management decisions.

FDA - U.S. Food and Drug Administration

8-8-2018

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA - U.S. Food and Drug Administration

7-8-2018

Dringende Sicherheitsinformation zu Condom von Reckitt Benckiser Healthcare International

Dringende Sicherheitsinformation zu Condom von Reckitt Benckiser Healthcare International

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

2-8-2018

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

Health Canada testing of “Jian Pai Natural Skin Care Cream,” also called ‘’Yikangshuang,” found that it contains two antifungal drugs (fluconazole and miconazole) that are not listed on the product label, and may pose serious health risks.

Health Canada

1-8-2018

Dringende Sicherheitsinformation zu ARTIS Q, ARTIS pheno von Siemens Healthcare GmbH Advanced Therapies

Dringende Sicherheitsinformation zu ARTIS Q, ARTIS pheno von Siemens Healthcare GmbH Advanced Therapies

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

1-8-2018

Dringende Sicherheitsinformation zu Ceiling Stand 3D TOP, Ceiling Stand 3D V von Siemens Healthcare GmbH - Diagnostic Imaging

Dringende Sicherheitsinformation zu Ceiling Stand 3D TOP, Ceiling Stand 3D V von Siemens Healthcare GmbH - Diagnostic Imaging

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

28-7-2018

Dringende Sicherheitsinformation zu Carescape R860 von GE Healthcare Technologies (Datex Ohmeda)

Dringende Sicherheitsinformation zu Carescape R860 von GE Healthcare Technologies (Datex Ohmeda)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

14-11-2018

Caring for a loved one? Be prepared for any situation. 4 tips to help you keep you loved one safe:  http://www.fda.gov/caregivertips  #NationalFamilyCaregiversMonthpic.twitter.com/DpNpz8NCDe

Caring for a loved one? Be prepared for any situation. 4 tips to help you keep you loved one safe: http://www.fda.gov/caregivertips  #NationalFamilyCaregiversMonthpic.twitter.com/DpNpz8NCDe

Caring for a loved one? Be prepared for any situation. 4 tips to help you keep you loved one safe: http://www.fda.gov/caregivertips  #NationalFamilyCaregiversMonth pic.twitter.com/DpNpz8NCDe

FDA - U.S. Food and Drug Administration

1-11-2018

The @US_FDA issues a letter to health care providers regarding possible battery failure in Getinge's Maquet/Datascope intra-aortic balloon pumps. Read the letter here:  https://go.usa.gov/xPyHT  #MedicalDevice

The @US_FDA issues a letter to health care providers regarding possible battery failure in Getinge's Maquet/Datascope intra-aortic balloon pumps. Read the letter here: https://go.usa.gov/xPyHT  #MedicalDevice

The @US_FDA issues a letter to health care providers regarding possible battery failure in Getinge's Maquet/Datascope intra-aortic balloon pumps. Read the letter here: https://go.usa.gov/xPyHT  #MedicalDevice

FDA - U.S. Food and Drug Administration

1-11-2018

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here:  https://go.u

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here: https://go.u

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here: https://go.usa.gov/xPysF  #MedicalDevice

FDA - U.S. Food and Drug Administration

22-10-2018

Velphoro (Vifor Fresenius Medical Care Renal Pharma France)

Velphoro (Vifor Fresenius Medical Care Renal Pharma France)

Velphoro (Active substance: mixture of polynuclear iron(iii)-oxyhydroxide, sucrose and starches) - Centralised - Yearly update - Commission Decision (2018)6972 of Mon, 22 Oct 2018

Europe -DG Health and Food Safety

18-10-2018

Kivexa (ViiV Healthcare BV)

Kivexa (ViiV Healthcare BV)

Kivexa (Active substance: abacavir / Lamivudine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6924 of Thu, 18 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000581/T/0076

Europe -DG Health and Food Safety

2-10-2018

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Active substance: esomeprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6474 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/002618/T/0023

Europe -DG Health and Food Safety

2-10-2018

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6480 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Trizivir (ViiV Healthcare BV)

Trizivir (ViiV Healthcare BV)

Trizivir (Active substance: abacavir, lamivudine, zidovudine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6483 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/338/T/108

Europe -DG Health and Food Safety

2-10-2018

Telzir (ViiV Healthcare BV)

Telzir (ViiV Healthcare BV)

Telzir (Active substance: Fosamprenavir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6468 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/534/T/93

Europe -DG Health and Food Safety

2-10-2018

Celsentri (ViiV Healthcare BV)

Celsentri (ViiV Healthcare BV)

Celsentri (Active substance: maraviroc) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6467 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/811/T/56

Europe -DG Health and Food Safety

25-9-2018

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices:  http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: https://go.usa.gov/xPjCj  pic.twitter.com/yVSNlc5Qb0

FDA - U.S. Food and Drug Administration

25-9-2018

Pelgraz (Accord Healthcare Limited)

Pelgraz (Accord Healthcare Limited)

Pelgraz (Active substance: pegfilgrastim) - Centralised - Authorisation - Commission Decision (2018)6288 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/003961/0000

Europe -DG Health and Food Safety

24-9-2018

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments:  https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX  pic.twitter.com/iQsKIAAQTn

FDA - U.S. Food and Drug Administration

24-9-2018

Blitzima (Celltrion Healthcare Hungary Kft.)

Blitzima (Celltrion Healthcare Hungary Kft.)

Blitzima (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6228 of Mon, 24 Sep 2018

Europe -DG Health and Food Safety

24-9-2018

Lenalidomide Accord (Accord Healthcare Limited)

Lenalidomide Accord (Accord Healthcare Limited)

Lenalidomide Accord (Active substance: lenalidomide) - Centralised - Authorisation - Commission Decision (2018)6237 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4857

Europe -DG Health and Food Safety

19-9-2018

 12th Pharmacovigilance stakeholder forum, European Medicines Agency, London, UK, From: 24-Sep-2018, To: 24-Sep-2018

12th Pharmacovigilance stakeholder forum, European Medicines Agency, London, UK, From: 24-Sep-2018, To: 24-Sep-2018

This forum brings together regulators with patients, healthcare professionals and industry, to take stock of what we have achieved and what needs to be the focus over the coming years.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

This Healthcare Professionals' Working Party (HCPWP) plenary meeting will include discussions on advances in clinical practice and the scientific and regulatory challenges. Members will also be invited to present how they are including regulatory sciences in fellowships and young researchers’ training. Feedback will be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

This joint Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) meeting will include results of the 2017 EMA perception survey. EMA regulatory science to 2025 will be discussed together with updates on Good Pharmacovigilance Practices (GVP). The Topic Group on Digital media and health will feedback to the working parties’ members. Participants will also receive an update on ongoing work on electronic product information and on availability of authorised med...

Europe - EMA - European Medicines Agency

7-9-2018

Newsletter:  Human medicines highlights - September 2018

Newsletter: Human medicines highlights - September 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

29-8-2018

Cortacare (Ecuphar NV)

Cortacare (Ecuphar NV)

Cortacare (Active substance: Hydrocortisone aceponate) - Centralised - Authorisation - Commission Decision (2018)5781 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4689

Europe -DG Health and Food Safety

25-8-2018

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety  https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.gov/xUuSb  #OnePairTakeCare pic.twitter.com/hNCAOAmJVQ

FDA - U.S. Food and Drug Administration

24-8-2018

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

FDA - U.S. Food and Drug Administration

23-8-2018

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCarepic.twitter.com/u4VcqcA2uJ

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCarepic.twitter.com/u4VcqcA2uJ

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCare pic.twitter.com/u4VcqcA2uJ

FDA - U.S. Food and Drug Administration

22-8-2018

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevice pic.twitter.com/SQYFz30oFy

FDA - U.S. Food and Drug Administration

22-8-2018

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCarepic.twitter.com/Gnez9sxXgE

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCarepic.twitter.com/Gnez9sxXgE

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCare pic.twitter.com/Gnez9sxXgE

FDA - U.S. Food and Drug Administration

22-8-2018

Cholib (Mylan IRE Healthcare Ltd)

Cholib (Mylan IRE Healthcare Ltd)

Cholib (Active substance: fenofibrate / simvastatin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5632 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2559/T/20

Europe -DG Health and Food Safety

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

21-8-2018

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals:  https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCarepic.twitt

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals: https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCarepic.twitt

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals: https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCare pic.twitter.com/PcxUGHgwoV

FDA - U.S. Food and Drug Administration

21-8-2018

Always use contact lens solution, not water, to clean and store your lenses!  #OnePairTakeCare  https://go.usa.gov/xUs89 pic.twitter.com/Jm50z0UFVu

Always use contact lens solution, not water, to clean and store your lenses! #OnePairTakeCare https://go.usa.gov/xUs89 pic.twitter.com/Jm50z0UFVu

Always use contact lens solution, not water, to clean and store your lenses! #OnePairTakeCare https://go.usa.gov/xUs89  pic.twitter.com/Jm50z0UFVu

FDA - U.S. Food and Drug Administration

20-8-2018

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care.  https://www.facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/Akf1Dz93Xx

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care. https://www.facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/Akf1Dz93Xx

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care. https://www.facebook.com/CDC/  #OnePairTakeCare pic.twitter.com/Akf1Dz93Xx

FDA - U.S. Food and Drug Administration

20-8-2018

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCarepic.twitter.com/jxiBHA3CiT

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCarepic.twitter.com/jxiBHA3CiT

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCare pic.twitter.com/jxiBHA3CiT

FDA - U.S. Food and Drug Administration

17-8-2018

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use.  http://facebook.com/CDC/   #OnePairTakeCarepic.twitter.com/7HDQYrdPBv

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use. http://facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/7HDQYrdPBv

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use. http://facebook.com/CDC/  #OnePairTakeCare pic.twitter.com/7HDQYrdPBv

FDA - U.S. Food and Drug Administration

17-8-2018

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System.  https://go.usa.gov/xUeYd  #MedicalDevices

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System. https://go.usa.gov/xUeYd  #MedicalDevices

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System. https://go.usa.gov/xUeYd  #MedicalDevices

FDA - U.S. Food and Drug Administration

8-8-2018

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests   https://go.usa.gov/xUAt4  #MedicalDevice #FDA

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests https://go.usa.gov/xUAt4  #MedicalDevice #FDA

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests https://go.usa.gov/xUAt4  #MedicalDevice #FDA

FDA - U.S. Food and Drug Administration

7-8-2018

Accofil (Accord Healthcare Limited)

Accofil (Accord Healthcare Limited)

Accofil (Active substance: Filgrastim) - Centralised - Yearly update - Commission Decision (2018)5428 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

Memantine Accord (Accord Healthcare Limited)

Memantine Accord (Accord Healthcare Limited)

Memantine Accord (Active substance: memantine) - Centralised - Renewal - Commission Decision (2018)5421 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2766/R/10

Europe -DG Health and Food Safety

6-8-2018

Human medicines highlights - August 2018

Human medicines highlights - August 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

6-8-2018

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)5386 of Mon, 06 Aug 2018

Europe -DG Health and Food Safety